Compare Bristol-Myers Squibb Co (BMY) vs US Global Jets ETF (JETS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs US Global Jets ETF — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while US Global Jets ETF trades at $30.99. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals.
| BMY | JETS | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Sector/Thematic |
52-Week High | $62.37 | $33.34 |
52-Week Low | $42.60 | $23.12 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
JETS trades at $31.22, down 2.71% amid Middle East tensions driving fuel costs higher. Technical signals are mixed with a bullish moving average trend but neutral oscillators, while RSI_6 at 20.52 suggests potential oversold conditions. Recent news highlights airline profit pressures from surging fuel expenses, with the global industry slashing 2026 forecasts due to conflict impacts.
Outlook remains cautious as fuel price volatility and geopolitical risks overshadow cyclical recovery potential. Investment opportunity hinges on oil price stabilization and travel demand resilience, but near-term headwinds from elevated costs and competitive gaps pose significant risks to shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
